

Specimen Collected: 8/12/2026 15:32 MDT

A1 Antigen Typing, Patient	Received: 8/13/2026 13:25 MDT	Report/Verified: 8/13/2026 13:50 MDT
-----------------------------------	--------------------------------------	---

Procedure	Result	Units	Reference Interval
A1 (ABO4) Antigen Typing, Patient	Negative ^{f1}		

AB Ident Panel-Cold (IRL)	Received: 8/13/2026 13:25 MDT	Report/Verified: 8/13/2026 13:50 MDT
----------------------------------	--------------------------------------	---

Procedure	Result	Units	Reference Interval
Cold Panel Identification	Done		

ABORH Discrepancy Investigation, IRL	Received: 8/13/2026 13:25 MDT	Report/Verified: 8/13/2026 13:50 MDT
---	--------------------------------------	---

Procedure	Result	Units	Reference Interval
ABORh	See Note ^{f2}		

Elution And Antibody Identification, RBC	Received: 8/13/2026 13:25 MDT	Report/Verified: 8/13/2026 13:50 MDT
---	--------------------------------------	---

Procedure	Result	Units	Reference Interval
Interp Elution	See Below ^{t1}		

Warm Auto Adsorption	Received: 8/13/2026 13:25 MDT	Report/Verified: 8/13/2026 13:50 MDT
-----------------------------	--------------------------------------	---

Procedure	Result	Units	Reference Interval
NBR Warm Auto Adsorptions	1		

Interpretive Text

t1: 8/12/2026 15:32 MDT (Interp Elution)

Elution studies performed as part of an ABO Discrepancy investigation.

Result Footnote

f1: A1 (ABO4) Antigen Typing, Patient

This patient appears to be a subgroup of A (ABO:-4) (A1 lectin negative).

f2: ABORh

An ABO discrepancy was observed using routine test methods. The patient appears to be a weak subgroup of A and Rh Positive.

Adsorption and elution studies were required to demonstrate the presence of the A antigen. No reactivity was observed when testing the patient's red cells with commercial anti-A, anti-A1 lectin, or anti-B reagents. Serum reverse grouping revealed strong reactive anti-B and weak anti-A1 reactivity but found no reactivity with group A2 red cells. This type of reactivity pattern is consistent with a weak subgroup of A. Confirmation of these results by a molecular test method is recommended.

Anti-A1 is generally considered clinically insignificant with regard to red cell transfusion.

If red cell transfusion is required for the patient, the institution's policy for selecting units for a patient with an ABO discrepancy should be followed.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 26-224-900156**Report Request ID:** 21652030**Printed:** 8/13/2026 15:40 MDT

Page 1 of 1